Evaluation of Safe and Effectiveness of an Injectable Solution Acid Deoxycholic Based for Reduction of Localized Adiposities

Abstract

Background:The use of deoxycholic acid to reduce localized fat deposits is a procedure that has been in use for about 30 years. Its effectiveness as treatment is due to emulsification of phospholipids and therefore, solubilization of the biological membranes with resulting fat necrosis. The purpose of the study was to assess the effectiveness and the safety of an injectable solution containing sodium deoxycholtate 1.25% (DB125), used as intralipotherapy.Methods:The effectiveness and safety of DB125 solution have been assessed with a multicentre observational prospective study carried out between February and October 2017. The 221 selected patients presented with various forms and degrees of localized fat in several areas. Intralipotherapy treatments were performed 6 weeks apart and until the clinical result was obtained. Aesthetic outcomes were evaluated by the authors using preoperative and postoperative photographic documentation and by the patients with their level of satisfaction by filling out an anonymous form. Major adverse events were reported by each doctor who performed the treatment.Results:Two hundred twenty-one patients treated in 273 cases of different localized fat deposits. One hundred eighty-five patients who could be assessed for final results gave the effectiveness of the treatment an average score of 7.4. The failure percentage of the treatment was 3.8%. The medical evaluation showed treatment success in 93.5% of cases. Adverse events can be divided into 2 groups: minor adverse events, which are very frequent and major ones, which are extremely rare. For both groups, the adverse events can be ascribed to localized problems in the treatment area.Conclusion:Studies have shown that the second-generation solution containing sodium deoxycholate 1.25% is effective and safe to treat different localized fat deposits. The high degree of effectiveness shown in the study was not associated with a lesser degree of handling because, at the doses indicated and with the use of intralipotherapy, the occurrence of adverse events was minimal.

Alternative Cosmetic and Medical Applications of Injectable Deoxycholic Acid: A Systematic Review

“…29–39 Fifteen of them were conducted in the United States, 21–23,26,27,29–31,34–39 2 in Italy, 24,25 1 in Canada, 28 and 1 in Saudi Arabia. 32 All studies used 1% DCA except the 2 conducted in Italy which used 1.25%, 24,25 and 1 study used 1.0%, 2.5%, and 5%. 27…”

“…26–28 With the NIH assessment tool, all 5 before–after studies have overall moderate risk of bias with concerns in sample size, follow-up rate, statistical analysis, and multiple outcome measures (See SDCAppendix III—SDCTable S3, Supplemental Digital Content 4 , http://links.lww.com/DSS/A856). 21–25…”

“…One multicenter observational prospective study treated 273 cases of localized fat deposits in 221 patients (71.9% females) at various body sites with injectable DCA, including 57 abdomen, 51 flanks, 42 saddle bag thighs, 38 inner knees, 29 inner thighs, 26 back rolls, 17 arms, 8 pseudogynecomastia, and 5 buffalo humps. 24 125 mg/10 mL (1.25%) of DCA was used for each 100 cm 2 over the localized fat deposits (1.25 mg/cm 2 ). 232 of the cases were analyzed and showed an overall success rate of 93.5% (Figure 1).…”

“…The 19 studies, published from 2005 to 2020, include 5 interventional studies, [21][22][23][24][25] 3 case series, [26][27][28] and 11 case reports. [29][30][31][32][33][34][35][36][37][38][39] Fifteen of them were conducted in the United States, [21][22][23]26,27,[29][30][31][34][35][36][37][38][39] 2 in Italy, 24,25 1 in Canada, 28 and 1 in Saudi Arabia.…”

Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid

“…Cholic acid is used to treat patients with genetic deficiencies in the synthesis of bile acids due to single enzyme deficiencies; the typical dose is 10 to 15 mg/kg once daily (27). DoC has been utilized in humans at a concentration of 15 mg/kg/day to decrease plasma high-density lipoprotein (HDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol (27) and it is also FDA-approved to reduce fat deposits (28,29).…”